Candel Therapeutics (CADL) Payables (2020 - 2025)
Candel Therapeutics (CADL) posted Payables of $1.1 million for Q4 2025, up 0.98% sequentially from $1.1 million in Q3 2025, and up 376.37% YoY from $237000.0 in Q4 2024.
Candel Therapeutics (CADL) Payables (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Payables for 6 years, with the latest figure at $1.1 million in Q4 2025.
- Quarterly Payables rose 376.37% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (up 376.37% YoY) and the FY2025 annual result came in at $1.1 million, up 376.37% from the prior year.
- Payables improved to $1.1 million in Q4 2025 per CADL's latest filing, from $1.1 million in the prior quarter.
- Over five years, Payables peaked at $2.0 million in Q2 2025 and troughed at $237000.0 in Q4 2024.
- A 5-year average of $828210.5 and a median of $759000.0 in 2021 frame the typical range for Payables.
- The sharpest annual moves came in 2022 and 2025: Payables tumbled 76.1% in 2022, then surged 376.37% in 2025.
- Over 5 years, Payables stood at $1.6 million in 2021, then sank by 76.1% to $380000.0 in 2022, then gained by 11.05% to $422000.0 in 2023, then tumbled by 43.84% to $237000.0 in 2024, then soared by 376.37% to $1.1 million in 2025.
- According to Business Quant data, Payables over the past three periods registered $1.1 million, $1.1 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | 1.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | 1.12 Mn |
| Jun 30, 2025 | 1.95 Mn |
| Mar 31, 2025 | 760,000.00 |
| Dec 31, 2024 | 237,000.00 |
| Sep 30, 2024 | 296,000.00 |
| Jun 30, 2024 | 433,000.00 |
| Mar 31, 2024 | 472,000.00 |
| Dec 31, 2023 | 422,000.00 |
| Sep 30, 2023 | 250,000.00 |
| Jun 30, 2023 | 480,000.00 |
| Mar 31, 2023 | 592,000.00 |
| Dec 31, 2022 | 380,000.00 |
| Sep 30, 2022 | 970,000.00 |
| Jun 30, 2022 | 1.58 Mn |
| Mar 31, 2022 | 1.39 Mn |
| Dec 31, 2021 | 1.59 Mn |
| Sep 30, 2021 | 925,000.00 |
| Jun 30, 2021 | 759,000.00 |
| Dec 31, 2020 | 921,000.00 |